Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 1, 2026, 1:14 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 1,572 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Period B Clear all
Recruiting Not applicable Interventional

Promoting Well-being and Health in Heart Failure

NCT04829617
View directory record Official record
Conditions
Heart Failure, Heart Failure NYHA Class I, Heart Failure NYHA Class II, Heart Failure NYHA Class III
Interventions
PP-MI Intervention, MI-alone Intervention
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Nov 1, 2026, 1:14 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of MK-2060 in Healthy Participants (MK-2060-016)

NCT06582602
View directory record Official record
Conditions
Venous Thrombosis
Interventions
MK-2060, Placebo
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 50 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
2
States / cities
Miami, Florida • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Nov 1, 2026, 1:14 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Food-Effect, Drug-Drug Interaction, and Pharmacokinetics Study of NX-5948 in Healthy Adult Subjects

NCT06593457
View directory record Official record
Conditions
Healthy Volunteers
Interventions
IP, Matching Placebo
Drug
Lead sponsor
Nurix Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Mar 14, 2025 · Synced Nov 1, 2026, 1:14 AM EST
Completed Phase 1 Interventional

Extension Study for Patients Who Had Not Met Criteria for Discontinuation in Previous Sponsored Belinostat Trials

NCT04184869
View directory record Official record
Conditions
Solid Tumor, Hematological Malignancies
Interventions
Belinostat, Atazanavir
Drug
Lead sponsor
Acrotech Biopharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated May 3, 2023 · Synced Nov 1, 2026, 1:14 AM EST
Completed Phase 1Phase 2 Interventional Results available

A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia

NCT02733042
View directory record Official record
Conditions
Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell
Interventions
Durvalumab, Lenalidomide, Rituximab, Ibrutinib, Bendamustine
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
19
States / cities
Gilbert, Arizona • Scottsdale, Arizona • Aurora, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2023 · Synced Nov 1, 2026, 1:14 AM EST
Active, not recruiting Phase 2 Interventional

A Study to Compare Different Doses of RO7795081 With Placebo or Semaglutide in People With Type 2 Diabetes

NCT07112872
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
RO7795081, Semaglutide, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
21
States / cities
Tucson, Arizona • Lake Forest, California • Rancho Cucamonga, California + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Nov 1, 2026, 1:14 AM EST
Terminated Not applicable Interventional Results available

Treatment of Severe Destructive Behavior: FCT Versus Wait-List Control

NCT02483572
View directory record Official record
Conditions
Aggression, Self-Injurious Behavior
Interventions
Functional Communication Training
Behavioral
Lead sponsor
University of Nebraska
Other
Eligibility
3 Years to 18 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 18, 2023 · Synced Nov 1, 2026, 1:14 AM EST
Completed Phase 1Phase 2 Interventional Results available

Phase I/II Study of SGI-110 With Irinotecan Versus Regorafenib or TAS-102 in Metastatic Colorectal Cancer

NCT01896856
View directory record Official record
Conditions
Previously Treated Metastatic Colorectal Cancer
Interventions
SGI-110 Dose Escalation, Regorafenib, TAS-102, SGI-110, Irinotecan
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
3
States / cities
Los Angeles, California • Baltimore, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 6, 2020 · Synced Nov 1, 2026, 1:14 AM EST
Terminated Phase 1 Interventional

Treatment of B-CLL With Autologous IL2 and CD40 Ligand-Expressing Tumor Cells + Lenalidomide

NCT01604031
View directory record Official record
Conditions
B-cell Chronic Lymphocytic Leukemia
Interventions
B-CLL Vaccine, Lenalidomide
Biological · Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 75 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 8, 2016 · Synced Nov 1, 2026, 1:14 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Well-Being and Physical Activity Study

NCT03194854
View directory record Official record
Conditions
Health Promotion
Interventions
Fun For Wellness (FFW)
Behavioral
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 64 Years
Enrollment
900 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Coral Gables, Florida
Source: ClinicalTrials.gov public record
Updated Apr 21, 2022 · Synced Nov 1, 2026, 1:14 AM EST
Terminated Phase 1Phase 2 Interventional Results available

Atezolizumab in Combination With Entinostat and Bevacizumab in Patients With Advanced Renal Cell Carcinoma

NCT03024437
View directory record Official record
Conditions
Metastatic Cancer, Renal Cancer
Interventions
Atezolizumab, Bevacizumab, Entinostat
Drug
Lead sponsor
Roberto Pili
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
4
States / cities
Indianapolis, Indiana • Columbus, Ohio • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 20, 2025 · Synced Nov 1, 2026, 1:14 AM EST
Active, not recruiting Phase 2Phase 3 Interventional

An Efficacy and Safety Study of Basimglurant (NOE-101) in Patients With Trigeminal Neuralgia.

NCT05217628
View directory record Official record
Conditions
Trigeminal Neuralgia
Interventions
Basimglurant, Placebo
Drug · Other
Lead sponsor
Noema Pharma AG
Industry
Eligibility
18 Years to 75 Years
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
8
States / cities
La Jolla, California • Miami, Florida • Tampa, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Nov 1, 2026, 1:14 AM EST
Completed Phase 2 Interventional Results available

Bracing and Strengthening for Posterior Tibial Tendon Dysfunction

NCT00756457
View directory record Official record
Conditions
Posterior Tibial Tendon Dysfunction
Interventions
Bracing, Strengthening exercises, Stretching exercises
Device · Other
Lead sponsor
Ithaca College
Other
Eligibility
40 Years to 80 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jul 2, 2014 · Synced Nov 1, 2026, 1:14 AM EST
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Effects of Carbohydrate in Diet and Supplements on the Gastrointestinal Tolerability of LIK066

NCT03198767
View directory record Official record
Conditions
Obesity
Interventions
LIK066, Carbohydrate 50%, Carbohydrate 25%, Carbohydrate 8%, Carbohydrate 0%, Psyllium, Calcium carbonate
Drug · Dietary Supplement
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Nov 1, 2026, 1:14 AM EST
Active, not recruiting Phase 3 Interventional

A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine

NCT07018700
View directory record Official record
Conditions
Episodic Migraine
Interventions
Xeomin, Placebo
Drug
Lead sponsor
Merz Therapeutics GmbH
Industry
Eligibility
18 Years and older
Enrollment
997 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
47
States / cities
Chandler, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 43 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Nov 1, 2026, 1:14 AM EST
Terminated Phase 3 Interventional Results available

Study of Perampanel as Adjunctive Treatment for Inadequately Controlled Seizures Associated With Lennox-Gastaut Syndrome

NCT02834793
View directory record Official record
Conditions
Lennox-Gastaut Syndrome (LGS)
Interventions
Placebo, Perampanel
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
2 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
31
States / cities
Little Rock, Arkansas • Palo Alto, California • Gulf Breeze, Florida + 25 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2022 · Synced Nov 1, 2026, 1:14 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY3202626 in Healthy Participants and Participants With Alzheimer's Disease

NCT02323334
View directory record Official record
Conditions
Healthy Volunteers, Alzheimer Disease
Interventions
LY3202626, Placebo (Part A, B, C), Itraconazole
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
20 Years and older
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Apr 19, 2021 · Synced Nov 1, 2026, 1:14 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Comparative Bioavailability of BMS-986278 in Healthy Participants

NCT06715683
View directory record Official record
Conditions
Healthy Volunteers
Interventions
BMS-986278 Batched method, Dose A, BMS-986278 Batched method, Dose B, BMS-986278 Continuous method
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Apr 4, 2025 · Synced Nov 1, 2026, 1:14 AM EST
Completed Phase 2 Interventional Results available

A New Oral Treatment For Type II Diabetes Mellitus

NCT00111800
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Placebo, DEN 2.5 mg, DEN 7.5 mg, DEN 15 mg, DEN 30 mg, DEN 45 mg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
36
States / cities
Long Beach, California • Pasadena, California • Denver, Colorado + 32 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2018 · Synced Nov 1, 2026, 1:14 AM EST
Active, not recruiting Phase 2 Interventional

N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma

NCT06061809
View directory record Official record
Conditions
Glioblastoma
Interventions
Bevacizumab, PD-L1 t-haNK, N-803, Tumor Treating Fields (TTFields, 200 kHz)
Drug · Device
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
4
States / cities
El Segundo, California • Fullerton, California • Newport Beach, California + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Nov 1, 2026, 1:14 AM EST
Terminated Phase 1 Interventional

Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies

NCT01744912
View directory record Official record
Conditions
Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, B-cell Lymphomas, Marginal Zone Lymphoma, Mantle Cell Lymphoma, Waldenstrom's Macroglobulinemia
Interventions
Ublituximab, Lenalidomide
Drug
Lead sponsor
TG Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
2
States / cities
Huntsville, Alabama • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 11, 2022 · Synced Nov 1, 2026, 1:14 AM EST
Completed Not applicable Interventional

Using Smartphones to Provide Recovery Support Services

NCT02132481
View directory record Official record
Conditions
Substance Use Disorder (SUD), Recovery
Interventions
EMA Only, EMI Only, EMA+EMI, Neither - RSAU
Other
Lead sponsor
Chestnut Health Systems
Other
Eligibility
18 Years and older
Enrollment
401 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
3
States / cities
Chicago, Illinois • Normal, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 28, 2021 · Synced Nov 1, 2026, 1:14 AM EST
Completed Phase 1 Interventional

A Study to Determine the Effect of Food on the Pharmacokinetics of PCI-32765

NCT01820936
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Sequence 1: PCI-32765, Sequence 2: PCI-32765, Sequence 3: PCI-32765, Sequence 4: PCI-32765, Sequence 5: PCI-32765
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Neptune City, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 15, 2014 · Synced Nov 1, 2026, 1:14 AM EST
Completed Phase 2Phase 3 Interventional Results available

MEmbranous Nephropathy Trial Of Rituximab

NCT01180036
View directory record Official record
Conditions
Idiopathic Membranous Nephropathy
Interventions
Rituximab, Cyclosporine
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
18
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2019 · Synced Nov 1, 2026, 1:14 AM EST